Loading
Spore.Bio
Spore.Bio develops technology for rapid microbiology testing that uses light-based sensing and AI to detect and quantify microbial contamination in products across industries like food, beverages, cosmetics, pharmaceuticals, and water systems. The company’s platform combines machine learning models with photonic data to produce near-real-time insights about bacterial presence without the long incubation times required by traditional lab methods. Spore.Bio also integrates testing hardware with analytical dashboards that help quality teams monitor contamination trends and process data. The firm collaborates with scientific partners to expand its microbial datasets and continuously refine detection models. Its offerings aim to support manufacturers in transitioning from delayed lab testing toward faster contamination awareness and response.
Funding
Every round, secondary, debt facility or acquisition involving Spore.Bio that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—